Drug Patents owned by Salix Pharms

1. Drug name - MOVIPREP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169381 SALIX PHARMS Colon cleansing compositions and methods
Sep, 2024

(1 year, 11 months from now)

US7658914 SALIX PHARMS Colon cleansing compositions
Sep, 2024

(1 year, 11 months from now)

CN1705494B SALIX PHARMS Colon Cleansing Composition
Oct, 2023

(1 year, 24 days from now)

CN101897721A SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

CN1705494A SALIX PHARMS Colon Cleansing Composition
Oct, 2023

(1 year, 24 days from now)

CN101897721B SALIX PHARMS Colon Cleaning Composition
Oct, 2023

(1 year, 24 days from now)

EP2014304A1 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP2014304B9 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP2314319A1 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP2014304A8 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP2314319B1 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP2014304B1 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP1567193B1 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

EP1567193A1 SALIX PHARMS Colon Cleansing Compositions
Oct, 2023

(1 year, 24 days from now)

More Information on Dosage
Strength Dosage Availability
4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM FOR SOLUTION;ORAL Prescription

2. Drug name - OSMOPREP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7687075 SALIX PHARMS Colonic purgative composition with soluble binding agent
Jun, 2028

(5 years from now)

CN101087593B SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

CN101087593A SALIX PHARMS Colon Cathartic Constituent Containing Dissoluble Adhesive
Nov, 2024

(2 years from now)

CN102648980A SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

CN102648980B SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

EP1682098A1 SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

EP2308476A1 SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

EP2308476B1 SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

EP1682098B1 SALIX PHARMS Colonic Purgative Composition With Soluble Binding Agent
Nov, 2024

(2 years from now)

More Information on Dosage
Strength Dosage Availability
0.398GM;1.102GM TABLET;ORAL Prescription

3. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone Apr, 2024

(1 year, 6 months from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone Apr, 2024

(1 year, 6 months from now)

US8552025 SALIX PHARMS Stable methylnaltrexone preparation Apr, 2024

(1 year, 6 months from now)

US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(7 years from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(7 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(7 years from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(7 years from now)

US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Dec, 2030

(8 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
8MG/0.4ML (8MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
12MG/0.6ML (12MG/0.6ML) SOLUTION;SUBCUTANEOUS Prescription

4. Drug name - XIFAXAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7045620 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
Jun, 2024

(1 year, 8 months from now)

US8158781 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(1 year, 8 months from now)

US8835452 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(1 year, 8 months from now)

US7612199 SALIX PHARMS Polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(1 year, 8 months from now)

US7902206 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(1 year, 8 months from now)

US7906542 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2025

(2 years from now)

US8741904 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(3 years from now)

US8193196 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Sep, 2027

(4 years from now)

CN1613858A SALIX PHARMS Polymorph Of Rifaximin, Preparation Method Thereof And Its Application In Medical Preparation
Apr, 2007

(15 years ago)

CN101260114A SALIX PHARMS Polymorphous Forms Of Rifaximin, Preparation Method For Their Production And Use Thereof In Medicinal Preparations
Mar, 2024

(1 year, 5 months from now)

CN101260115A SALIX PHARMS Polycrystalline Type Of Rifaximin, Production Method Thereof And Use Thereof In Medicinal Preparations
Mar, 2024

(1 year, 5 months from now)

CN101260114B SALIX PHARMS Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Mar, 2024

(1 year, 5 months from now)

CN1886408B SALIX PHARMS Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Mar, 2024

(1 year, 5 months from now)

CN1886408A SALIX PHARMS Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Mar, 2024

(1 year, 5 months from now)

CN101260115B SALIX PHARMS Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Mar, 2024

(1 year, 5 months from now)

CN1900077B SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Preparation And Use Thereof In Medicinal Preparations
Jul, 2025

(2 years from now)

CN1900077A SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations
Jul, 2025

(2 years from now)

IN200800106P1 SALIX PHARMS Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Nov, 2024

(2 years from now)

IN216296B SALIX PHARMS Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Nov, 2024

(2 years from now)

IN200503181P1 SALIX PHARMS Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Nov, 2024

(2 years from now)

IN254839B SALIX PHARMS Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations
Nov, 2024

(2 years from now)

IN280906B SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations
Jul, 2025

(2 years from now)

IN200501865I1 SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations
Jul, 2025

(2 years from now)

EP1676848B1 SALIX PHARMS Polymorphous Forms Of Rifaximin As Antibiotics
Mar, 2024

(1 year, 5 months from now)

EP1557421A1 SALIX PHARMS Polymorphous Form Of Rifaximin As Antibiotic
Mar, 2024

(1 year, 5 months from now)

EP1676847A1 SALIX PHARMS Polymorphous Forms Of Rifaximin As Antibiotics
Mar, 2024

(1 year, 5 months from now)

EP1676848A1 SALIX PHARMS Polymorphous Forms Of Rifaximin As Antibiotics
Mar, 2024

(1 year, 5 months from now)

EP1557421B1 SALIX PHARMS Polymorphous Form Of Rifaximin As Antibiotic
Mar, 2024

(1 year, 5 months from now)

EP1676847B1 SALIX PHARMS Polymorphous Forms Of Rifaximin As Antibiotics
Mar, 2024

(1 year, 5 months from now)

EP1698630A1 SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations
Mar, 2025

(2 years from now)

EP1698630B1 SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations
Mar, 2025

(2 years from now)

EP1698630A8 SALIX PHARMS New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8853231 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin Jun, 2024

(1 year, 8 months from now)

US8158644 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin Jun, 2024

(1 year, 8 months from now)

US7915275 SALIX PHARMS Use of polymorphic forms of rifaximin for medical preparations Feb, 2025

(2 years from now)

US8518949 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations Feb, 2026

(3 years from now)

US9271968 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations Feb, 2026

(3 years from now)

US10703763 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations Feb, 2026

(3 years from now)

US10456384 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS) Feb, 2029

(6 years from now)

US10765667 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS) Feb, 2029

(6 years from now)

US8309569 SALIX PHARMS Methods for treating diarrhea-associated irritable bowel syndrome Jul, 2029

(6 years from now)

US7928115 SALIX PHARMS Methods of treating travelers diarrhea and hepatic encephalopathy Jul, 2029

(6 years from now)

US8829017 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy Jul, 2029

(6 years from now)

US9421195 SALIX PHARMS Methods of treating hepatic encephalopathy Jul, 2029

(6 years from now)

US8946252 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy Jul, 2029

(6 years from now)

US10335397 SALIX PHARMS Methods of treating hepatic encephalopathy Jul, 2029

(6 years from now)

US9629828 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy Jul, 2029

(6 years from now)

US10314828 SALIX PHARMS Methods of treating hepatic encephalopathy Jul, 2029

(6 years from now)

US10709694 SALIX PHARMS Methods of treating hepatic encephalopathy Jul, 2029

(6 years from now)

US8969398 SALIX PHARMS Methods of treating hepatic encephalopathy Oct, 2029

(7 years from now)

US8642573 SALIX PHARMS Methods of treating hepatic encephalopathy Oct, 2029

(7 years from now)

Drugs and Companies using RIFAXIMIN ingredient

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; Method of treating travelers' diarrhea; Treatment of patients with hepatic encephalopathy (he); Reduction in risk of overt hepatic encephalopathy (he) recurrence; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; Reduction in risk of overt hepatic encephalopathy (he) in adults

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
550MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.